Cervical Dysplasia (CIN 1, 2, 3): What Each Grade Means and How It Is Treated

• Cervical dysplasia is pre-cancerous, not cancer. It is graded CIN 1 (mild), CIN 2 (moderate) and CIN 3 (severe) based on how deep the abnormal cells go.
• It is caused by persistent infection with high-risk HPV. Most HPV infections clear on their own within one to two years.
• CIN 1 is usually just watched, because about 60 percent clear up on their own. CIN 3 is almost always treated.
• Treatment (most often a quick LEEP procedure) cures more than 9 in 10 cases at the first attempt.
• Progression from dysplasia to cancer typically takes 10 to 20 years, which is why screening every 3 to 5 years catches it in time.
• The single biggest thing you can do is attend every follow-up appointment. Most cervical cancers happen in women who were never screened or never came back.

Cervical dysplasia means abnormal cells on the surface layer (the epithelium) of your cervix, the lower part of the uterus that opens into the vagina. These cells are not yet cancer, but they are not normal either. Left untreated over many years, some can slowly progress to cervical cancer, which is why doctors take them seriously and why catching them is genuinely a good outcome.

Most of these changes happen in one specific spot called the transformation zone, where the smooth outer cells of the cervix meet the glandular cells lining the inner canal. This is the area most vulnerable to HPV and where almost all dysplasia and cervical cancer begins. If you want to understand your own anatomy better, this guide on how to find and check your cervix is a useful companion.

Dysplasia is graded by how far the abnormal cells reach through the thickness of the surface layer. This gives the names you will see on your report:

Once abnormal cells break through the base of the surface layer into the deeper tissue, it is no longer called dysplasia. It becomes invasive cancer. Dysplasia, by definition, has not crossed that line, which is why treating it works so well.

You may also see newer wording on some reports. Pathologists increasingly group these as LSIL (low-grade, roughly CIN 1) and HSIL (high-grade, roughly CIN 2 and 3). Both naming systems describe the same thing. Less commonly, dysplasia can affect the glandular cells inside the cervical canal; this is called adenocarcinoma in situ (AIS) and needs slightly different, more careful management because it can sit higher up and be harder to reach.

Nearly all cervical dysplasia is caused by long-lasting infection with high-risk types of human papillomavirus (HPV), a very common virus passed on through skin-to-skin sexual contact. Two types, HPV 16 and 18, cause about 70 percent of cervical cancers worldwide. You can read more about the virus itself in our overview of HPV in India: types, symptoms and treatment and the broader human papillomavirus guide.

Here is the reassuring part: most HPV infections are temporary. Roughly 70 to 90 percent clear on their own within one to two years as your immune system clears the virus, taking any mild cell changes with them. This is exactly why CIN 1 so often resolves without treatment. Only the small fraction of infections that persist beyond two years are the ones that can drive higher-grade dysplasia over time.

Because HPV is so common (most sexually active adults catch it at some point), a diagnosis is not a sign of anything you did wrong, and it cannot be reliably dated. The virus can stay quiet for years before causing changes, so it tells you nothing about a partner's faithfulness or yours. Treating dysplasia like any other medical condition, rather than a verdict on your sex life, makes the whole experience easier.

Some factors make it more likely that an HPV infection will persist and progress rather than clear:

Cervical dysplasia almost never causes symptoms. There is usually no pain, no unusual bleeding, and no discharge. This is precisely why it is found through screening rather than because something feels wrong, and it is the whole reason regular cervical cancer screening matters so much.

Because dysplasia is silent, do not wait for a symptom to tell you something is wrong. By the time symptoms like bleeding after sex, bleeding between periods, or a persistent unusual discharge appear, they point to a possible later-stage problem rather than early dysplasia. If you ever do notice such changes, get them checked promptly rather than assuming it is nothing; our guide on normal versus abnormal vaginal discharge can help you tell the difference.

Mild bleeding or spotting can also have completely harmless causes, such as cervical erosion or ectropion, which is unrelated to dysplasia. Only a clinical examination and the right test can tell these apart, so the safe move is always to ask rather than self-diagnose.

Diagnosis follows a clear three-step path: a screening test flags a possible problem, a colposcopy looks at the cervix closely, and a biopsy gives the final answer about the grade. Understanding this sequence makes the wait between steps far less frightening.

Step 1: Screening. This is either a Pap smear (which examines cells brushed from the cervix) or an HPV DNA test (which checks for high-risk virus), often done together. Current FOGSI and international guidance favours HPV testing as the primary screen for women aged 30 and above, repeated every five years if negative. If this is your first time, our walk-through of your first Pap smear in India explains exactly what to expect.

Step 2: Colposcopy. If screening is abnormal, the next step is a colposcopy. The doctor uses a speculum, paints the cervix with a mild vinegar solution that turns abnormal areas white, and examines it through a magnifying scope. It is done in a clinic, takes about 10 to 15 minutes, and feels similar to a Pap smear. Knowing what to expect before a pelvic exam can help if you feel anxious about the position.

Step 3: Biopsy. During colposcopy, a tiny sample of any suspicious area is taken and sent to a lab. This biopsy is what confirms the exact grade (CIN 1, 2 or 3). Some labs also run a p16 stain, which helps tell whether a borderline CIN 2 lesion is more likely to behave like a mild or a severe one, useful when deciding between watching and treating.

Results usually take one to two weeks. That wait is one of the hardest parts, so it is fine to ask your clinic for a clear timeline and a contact person. Typical Indian costs are roughly Rs 500 to 2,500 for a Pap smear, Rs 2,000 to 4,500 for an HPV test, and Rs 1,500 to 4,000 for a colposcopy with biopsy at private centres. At government and teaching hospitals such as AIIMS, JIPMER, PGI Chandigarh and Tata Memorial, these are free or heavily subsidised for referred patients.

CIN 1 is the mildest grade and the most common finding after an abnormal smear. The standard approach is watchful waiting, not immediate treatment, because the natural history is so favourable: about 60 percent of CIN 1 clears on its own within two years, around 30 percent stays the same, and only about 10 percent progresses to a higher grade.

Treating CIN 1 unnecessarily removes healthy cervical tissue for little benefit and can slightly raise the risk of preterm birth in a future pregnancy. So instead, your doctor will usually repeat HPV and Pap testing at around 12 months. If everything is normal, you return to routine screening. If CIN 1 persists for two years or progresses, treatment is then considered.

While you are being monitored, the most evidence-based thing you can do is stop smoking or chewing tobacco, which genuinely improves clearance rates; our tobacco cessation guide for Indian women covers the mPower quitline and nicotine replacement. General good health, sleep and balanced nutrition support your immune system too. Be cautious about supplements marketed as HPV cures; the evidence is weak and they are no substitute for follow-up.

If your situation is different, the plan adjusts. Very young women (early 20s) are monitored even more gently because HPV is so common and clears so readily at that age. In pregnancy, CIN 1 is simply watched and reassessed after delivery. Women with a weakened immune system, including those living with HIV, may be managed more actively; our guide on HIV in Indian women explains why.

CIN 2 sits in the middle, and so does its management. It behaves more variably than the other grades: some cases regress, but the progression risk is real enough that, for most women, treatment is the safer default. ACOG and FOGSI guidance broadly supports treating CIN 2 in women who do not fall into a specific watch-and-wait category.

However, observation can be a reasonable choice for selected younger women who are planning future pregnancies, where avoiding cervical surgery matters. Factors that favour watching rather than treating include young age, a small lesion, and a p16 stain that suggests the cells are likely to behave mildly. This is a shared decision: a good clinician will lay out the trade-offs and decide with you, not just for you.

If you are planning a baby in the near future, raise it directly, because it genuinely changes the calculation. The reproductive trade-offs (a small added preterm-birth risk after treatment versus the small progression risk while watching) are exactly the kind of thing worth discussing before you decide.

When treatment is chosen for CIN 2, it is the same procedure as for CIN 3, described in the next section, with the same high cure rate of over 90 percent.

CIN 3 is the most advanced grade of dysplasia and almost always needs treatment. Left untreated, roughly 30 percent of CIN 3 progresses to invasive cervical cancer over about 30 years. The good news is that treatment cures more than 90 percent of cases at the first attempt, and the small number of recurrences are usually caught early by follow-up.

LEEP (Loop Electrosurgical Excision Procedure) is the most common treatment, in India and worldwide. A thin, heated wire loop removes a small cone of tissue containing the abnormal area. It is done under local anaesthesia in a clinic, takes 10 to 15 minutes, and most women are back to normal life within a day or two. Expect some cramping and a watery or bloody discharge for two to four weeks, and avoid sex, tampons and strenuous exercise for four to six weeks while it heals. Private cost is typically Rs 8,000 to 25,000; free or minimal at government hospitals.

Cold knife conisation uses a scalpel rather than a heated wire and is done in an operating theatre under spinal or general anaesthesia. It is chosen when a larger or more precise cone is needed, especially when glandular changes (adenocarcinoma in situ) are suspected and clean edges are critical. Private cost is typically Rs 15,000 to 50,000.

A key advantage of these excisional methods is that the removed tissue is examined under the microscope, so any unexpected early cancer is not missed. This is why guidelines prefer them over older ablative methods (freezing or laser) for high-grade dysplasia.

After treatment, the lab reports the margins, the edges of the removed tissue. Clear (negative) margins mean the lesion was fully removed and recurrence risk is low. Involved (positive) margins mean some abnormal cells may remain, so closer follow-up or, sometimes, a repeat procedure is advised. Either way, the follow-up schedule in the next section is your safety net.

For complex cases or suspected glandular disease, ask for a referral to a gynaecological oncology unit. Centres such as AIIMS Delhi, Tata Memorial Mumbai, CMC Vellore, JIPMER and PGI Chandigarh, alongside large private hospitals, all offer comprehensive cervical dysplasia care.

Being treated is not quite the end of the story. Because women who have had high-grade dysplasia stay at a slightly raised risk for years, follow-up continues for at least 20 years, even past the usual screening-stop age. Knowing this upfront helps you stay engaged rather than disappearing once you feel well.

The usual schedule is an HPV and Pap test together at 6 and 12 months after treatment. If both are clear, you move to a combined test every three years. After several clear results over a few years, you return to routine screening but keep going long-term. If any test shows persistent HPV or abnormal cells, a colposcopy is repeated.

Recurrence happens in roughly 5 to 10 percent of women over five years, most often within the first two years, which is exactly the period the close follow-up is designed to catch. Stopping tobacco and treating any immune problems lowers this risk. If you are within the eligible age range and not yet vaccinated, the HPV vaccine (Cervavac or Gardasil) is worth discussing, as it may reduce the chance of new infections after treatment.

It is also completely normal for the run-up to each follow-up appointment to feel anxious. Many women describe a wave of worry in the weeks before a check. If this becomes hard to manage, that is a real and treatable thing; our guide on depression and anxiety in Indian women covers where to find support, and many cancer centres have counselling services open to women with pre-cancerous conditions too.

If dysplasia is found during pregnancy, the approach is reassuringly cautious: in almost all cases it is simply monitored through the pregnancy, with any definitive treatment done after delivery. Low and moderate-grade changes are very unlikely to progress meaningfully over nine months, and excisional treatment is avoided because of the small risks it carries during pregnancy.

Colposcopy can still be done safely in pregnancy by an experienced doctor, but biopsies are usually avoided unless cancer is genuinely suspected, and a sampling of the inner canal is not done at all during pregnancy. Your cervix may be checked once each trimester to confirm the lesion is stable.

Dysplasia does not affect how your baby is born. A normal vaginal delivery is safe with CIN 1, 2 or 3, and a caesarean is not needed just because of dysplasia. Definitive treatment is reviewed at your postpartum check; our guide to the 6-week postpartum checkup in India explains the timing.

If you have had a LEEP or cone before becoming pregnant, tell your obstetrician at your first booking visit. Past treatment slightly raises the risk of preterm birth, by roughly 1.5 to 2 times a baseline of about 8 percent in India, so the absolute risk stays modest. Where a lot of tissue was removed, your doctor may check your cervical length in the second trimester and, in selected cases, consider a cervical cerclage (a supportive stitch). For most women, prior treatment does not stop them having healthy, full-term pregnancies; if you want a fuller picture of the warning signs, see our guide on preterm labour and premature birth.

Treating dysplasia does not threaten your ability to get pregnant. LEEP and conisation remove a small amount of cervical surface tissue; they do not affect your ovaries, hormones or eggs. The conversations about fertility are really about future pregnancy outcomes, not about whether you can conceive.

The main thing to know is the small, modest rise in preterm-birth risk in a later pregnancy, mostly when a larger cone or repeat procedures were needed. Doctors limit this by removing only as much tissue as the lesion requires and avoiding repeat procedures where possible. A rare complication is cervical narrowing (stenosis), more likely after larger cones, which can cause painful periods or difficulty conceiving and is treatable with a minor dilation procedure.

If you are trying to conceive after a LEEP, most clinicians suggest waiting about three to six months for the cervix to heal first. After that, fertility is generally preserved. If you are also weighing up contraception while you decide on timing, our guide to birth control pills in India covers the options. The bottom line: for the vast majority of women, treating dysplasia supports their future family plans rather than getting in the way.

Cervical cancer remains one of the most common cancers in Indian women, with roughly 96,000 to over a lakh new cases a year according to ICMR registry data. The tragedy is that most cases are diagnosed late, not because treatments fail, but because fewer than one in ten eligible women have ever been screened. Finding and treating dysplasia early is the single most effective way to change this picture.

The infrastructure exists, though it is unevenly spread. Tertiary centres, AIIMS Delhi, JIPMER, PGI Chandigarh, Tata Memorial Mumbai, CMC Vellore and state cancer institutes, offer the full pathway from screening to surgery, usually free or heavily subsidised for referred patients, with the National Cancer Grid standardising protocols across 200-plus centres. Wait times can be long, but the quality of care is high.

Indicative private costs are: Pap smear Rs 500 to 1,500, HPV DNA test Rs 2,000 to 4,500, colposcopy with biopsy Rs 1,500 to 4,000, LEEP Rs 8,000 to 25,000, and cold knife conisation Rs 15,000 to 50,000. Schemes including Ayushman Bharat (PM-JAY), CGHS, ESIC and most private insurance cover cervical cancer prevention and treatment, though coverage of routine screening varies.

Access in rural areas is the real bottleneck. Programmes run by groups such as CAPED and the Indian Cancer Society bring free VIA (visual inspection with acetic acid) screening to villages, but following up an abnormal result often means travelling to a district hospital, which not every woman can manage. Closing this gap between screening and treatment is the main thing that would lower late-stage cervical cancer in India.

Cultural barriers matter too. Discomfort discussing reproductive health, fear of what an HPV diagnosis implies, and modesty around pelvic exams all delay care. Framing dysplasia as a routine, treatable condition, not a moral judgement, and involving supportive family members where appropriate, genuinely changes whether women come back for treatment.

Prevention has also taken a big step forward. India's own HPV vaccine Cervavac launched in 2022 at around Rs 2,000 per dose, far cheaper than Gardasil 9, and some states have started school-based programmes. The vaccine does not treat existing dysplasia, but combined with regular screening it offers near-complete protection against cervical cancer for the next generation.

Cervical dysplasia is usually silent, so the most important rule is to attend screening on schedule and to never skip a follow-up after an abnormal result. Beyond that, see a gynaecologist promptly if you notice any of the warning signs below. They do not mean you have cancer, but they always deserve a check.

• World Health Organization: Cervical cancer fact sheet
• ACOG: Abnormal Cervical Cancer Screening Test Results (FAQ)
• NHS: Colposcopy
• ICMR-NCDIR National Cancer Registry Programme
• ASCCP Risk-Based Management Consensus Guidelines
• FOGSI Good Clinical Practice Recommendations on Cervical Cancer Screening